This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

This study has been completed.
Asan Medical Center
Samsung Medical Center
Seoul National University Hospital
Ulsan University Hospital
Information provided by (Responsible Party):
Chong Kun Dang Pharmaceutical Identifier:
First received: November 26, 2009
Last updated: January 27, 2016
Last verified: January 2016
A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung Drug: Belotecan Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Single-Arm, Open-label, Multicenter, Phase 2 Clinical Trial to Assess the Efficacy and Safety of Single-Agent Camtobell Inj.(Belotecan) Administered on A Weekly Schedule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Previously Treated With Chemotherapy

Resource links provided by NLM:

Further study details as provided by Chong Kun Dang Pharmaceutical:

Primary Outcome Measures:
  • Objective Response Rate [ Time Frame: every 2 cyc ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 6 months after Last patient out ]
  • Progression Free survival [ Time Frame: 6 months after Last patient out ]
  • Adverse event [ Time Frame: every visit ]

Enrollment: 52
Study Start Date: September 2009
Study Completion Date: March 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Belotecan
Single arm
Drug: Belotecan
3.0 mg/m2, Day 1, 8, 15 every 4 weeks
Other Name: Camtobell inj.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 19 Years and older
  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC(Stage IIIB or IV)
  • ≥ one measureable or evaluable lesion, <25% of the bone marrow had been irradiated
  • prior platinum based chemotherapy
  • ECOG PS ≤ 2
  • Life expectancy > 3 months
  • Adequate organ function:

    • hematology: ANC ≥ 1.5×109/L, Platelet ≥ 100×109/L, hemoglobin ≥ 9.0g/dL
    • hepatic: total bilirubin ≤ 1.5×ULN, AST/ALT ≤ 2.0×ULN, ALP ≤2.0×ULN
    • renal: serum creatinine ≤ 1.5×ULN
  • Signed a written informed consent

Exclusion Criteria:

  • Active infection
  • Symptomatic brain lesion
  • Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix
  • Severe concurrent diseases
  • Prior anticancer therapy within 4 weeks before enroll
  • Active pregnancy test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Chong Kun Dang Pharmaceutical Identifier: NCT01022671     History of Changes
Other Study ID Numbers: 11NSCLC08K
Study First Received: November 26, 2009
Last Updated: January 27, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Chong Kun Dang Pharmaceutical:
Camtobell inj

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Phytogenic processed this record on July 26, 2017